# US 2011/0300180 A1 · Plant-derived vaccines against respiratory syncytial virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0300180 A1
- Document ID: US20110300180A1
- Status: Published application
- Kind: A1
- Application number: 13/194,194
- Filed: 2011-07-29
- Published: 2011-12-08
- Earliest claimed: 1999-05-11
- Assignees: Dennis E. Buetow
- Inventors: DENNIS E. BUETOW; SCHUYLER S. KORBAN; JAGDEEP SANDHU; SERGEI F. KRASNYANSKI
- Web page: https://patentgrep.com/patent/US20110300180A1

## CPC

- C07K 14/005: from viruses
- A61P 31/14: for RNA viruses
- C12N 15/8258: {for the production of oral vaccines (antigens) or immunoglobulins}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- C12N 2760/18522: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A plant-derived vaccine against respiratory syncytial virus (RSV) is disclosed. The vaccine includes an immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV coding sequence that encodes an antigenic protein of RSV. Also disclosed are methods of making the plant-derived vaccine of the invention, as well as transgenic plants, transgenic plant cells, and nucleic acid constructs useful in immunizing a mammal against RSV.

## Claims

### Claim 1

A chimeric nucleic acid construct for expression in plants comprising a nucleic acid molecule encoding an antigenic respiratory syncytial virus (RSV) protein or peptide, wherein said nucleic acid molecule is expressed in an edible portion of the plant, and wherein upon oral ingestion of the edible portion of the plant by a subject in need thereof, the antigenic RSV protein or peptide elicits a Th1 immune response in the subject.

### Claim 2 (depends on 1)

The chimeric nucleic acid construct of claim 1, further comprising an AMV RNA4 untranslated leader sequence as translational enhancer.

### Claim 3 (depends on 1)

The chimeric nucleic acid construct of claim 1, further comprising a P268 enhancer as transcriptional enhancer.

### Claim 4 (depends on 1)

The chimeric nucleic acid construct of claim 1, wherein the codons of the nucleic acid molecule encoding the antigenic RSV protein or peptide have been optimized for enhanced expression in plants.

### Claim 5 (depends on 1)

The chimeric nucleic acid construct of claim 1, wherein the antigenic RSV protein is RSV-F or RSV-G.

### Claim 6 (depends on 1)

A plant cell transformed with the chimeric nucleic acid construct of claim 1.

### Claim 7 (depends on 1)

A transgenic plant transformed with the chimeric nucleic acid construct of claim 1.

### Claim 8 (depends on 1)

A method for preparing an immunogenic complex comprising
growing plants cells transformed with the chimeric nucleic acid construct of claim 1, and
expressing the RSV protein or peptide in said plant cells to confer RSV antigen production in said plant cells.

### Claim 9 (depends on 1)

A method for preparing an immunogenic complex comprising
transforming a plant with the chimeric nucleic acid construct of claim 1 to produce a transgenic plant, and
expressing the RSV protein or peptide in said transgenic plant to confer RSV antigen production in said transgenic plant.

### Claim 10 (depends on 1)

An immunogenic complex comprising plant cells transformed with the chimeric nucleic acid construct of claim 1.

### Claim 11 (depends on 1)

An immunogenic complex comprising a transgenic plant transformed with the chimeric nucleic acid construct of claim 1.

### Claim 12 (depends on 1)

A method for eliciting a Th1 immune response in a subject comprising administering to a subject in need thereof an edible portion of a plant comprising the nucleic acid construct of claim 1 so that the antigenic RSV protein or peptide elicits a Th1 immune response.

### Claim 13 (depends on 12)

The method of claim 12, wherein said administration comprises a prime vaccination.

### Claim 14 (depends on 12)

The method of claim 12, wherein said administration comprises a boost vaccination.
